WALNUT EXTRACTS FOR NUTRACEUTICAL APPLICATIONS
원문보기
IPC분류정보
국가/구분
United States(US) Patent
공개
국제특허분류(IPC7판)
A61K-036/52
A61K-031/683
A61K-031/688
A61K-031/661
출원번호
US-0942223
(2015-11-16)
공개번호
US-0067295
(2016-03-10)
발명자
/ 주소
Eidenberger, Thomas
출원인 / 주소
Eidenberger, Thomas
인용정보
피인용 횟수 :
0인용 특허 :
0
초록▼
The invention describes to walnut oil extracts that have increased amounts of enriched in phospholipids, especially phosphatidylethanolamine (PE), phosphatidylcholine (PC), and phosphatidylinositol (PI) relative to walnut oil found in naturally occurring walnuts. It has been found that there are syn
The invention describes to walnut oil extracts that have increased amounts of enriched in phospholipids, especially phosphatidylethanolamine (PE), phosphatidylcholine (PC), and phosphatidylinositol (PI) relative to walnut oil found in naturally occurring walnuts. It has been found that there are synergistic therapeutic effects when PE/PC and/or PI are combined.
대표청구항▼
1. A method to treat a disease or condition related to the aggregation of β-amyloid, Alzheimer's disease, stroke, to improve blood-brain barrier function, to improve blood-brain barrier transport of an active agent across the blood-brain barrier, to improve or maintain cognitive health, to provide n
1. A method to treat a disease or condition related to the aggregation of β-amyloid, Alzheimer's disease, stroke, to improve blood-brain barrier function, to improve blood-brain barrier transport of an active agent across the blood-brain barrier, to improve or maintain cognitive health, to provide neuro-protection, to facilitate neural development and/or to facilitate cerebral metabolism comprising the step of providing to an individual an effective amount of a walnut extract composition comprising phosphatidylethanolamine (PE) and phosphatidylcholine (PC), wherein the ratio of PE to PC is greater than about 0.43 by weight, such that one or more of the conditions are treated, improved or facilitated. 2. The method of claim 1, further comprising phosphatidylinositol (PI). 3. The method of claim 2, further comprising a sphingolipid. 4. The method of claim 3, wherein the sphingolipid is sphingomyelin. 5. The method of claim 3, wherein the ratio of phospholipids/sphingolipids is above 5:1 by weight. 6. The method of claim 1, wherein the ratio of the unsaturated/saturated fatty acids is greater than about 1:1 by weight. 7. A method to treat a disease or condition related to the aggregation of β-amyloid, Alzheimer's disease, stroke, to improve blood-brain barrier function, to improve blood-brain barrier transport of an active agent across the blood-brain barrier, to improve or maintain cognitive health, to provide neuro-protection, to facilitate neural development and/or to facilitate cerebral metabolism comprising the step of providing to an individual an effective amount of a walnut extract composition comprising phosphatidylinositol (PI) and phosphatidylcholine (PC), wherein the ratio of PI to PC is greater than about 0.88 by weight, such that one or more of the conditions are treated, improved or facilitated. 8. The method of claim 7, further comprising phosphatidylethanolamine (PE). 9. The method of claim 8, further comprising a sphingolipid. 10. The method of claim 9, wherein the sphingolipid is sphingomyelin. 11. The method of claim 9, wherein the ratio of phospholipids/sphingolipids is above 5:1 by weight. 12. The method of claim 7, wherein the ratio of the unsaturated/saturated fatty acids is greater than about 1:1 by weight. 13. A method to treat a disease or condition related to the aggregation of β-amyloid, Alzheimer's disease, stroke, to improve blood-brain barrier function, to improve blood-brain barrier transport of an active agent across the blood-brain barrier, to improve or maintain cognitive health, to provide neuro-protection, to facilitate neural development and/or to facilitate cerebral metabolism comprising the step of providing to an individual an effective amount of a walnut extract composition comprising phosphatidylinositol (PI) and phosphatidylethanolamine (PE), wherein the ratio of PI to PE is greater than about 0.4 by weight, such that one or more of the conditions are treated, improved or facilitated. 14. The method of claim 13, further comprising phosphatidylcholine (PC). 15. The method of claim 14, further comprising a sphingolipid. 16. The method of claim 15, wherein the sphingolipid is sphingomyelin. 17. The method of claim 15, wherein the ratio of phospholipids/sphingolipids is above 5:1 by weight. 18. The method of claim 13, wherein the ratio of the unsaturated/saturated fatty acids is greater than about 1:1 by weight.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.